Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
Status:
Recruiting
Trial end date:
2025-06-15
Target enrollment:
Participant gender:
Summary
When administering clinical trial drugs to patients with house dust mite allergic rhinitis,
safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement
and immune activity of the disease are comparatively evaluated as secondary outcome.